Alliance Pharmaceutical has completed a previously announced round of private-placement financing, generating proceeds of $15.1 million. The San Diego-based vendor said it would use the investment to seek final Food and Drug Administration approval for its Imavist ultrasound contrast agent, continue clinical development of its Oxygent intravascular oxygen carrier, and for working capital.
By AuntMinnie.com staff writersDecember 3, 2001
Related Reading
Alliance completes reverse stock split, October 18, 2001
Alliance to launch prostate imaging study, October 8, 2001
Alliance wins patent interference ruling against Nycomed, September 20, 2001
Alliance closes in on Imavist clearance, August 20, 2001
Nycomed Amersham expands ultrasound efforts as Mallinckrodt exits sector, August 6, 2001
Copyright © 2001 AuntMinnie.com